The video this transcript is based on appeared on December 19.

NEW YORK (TheStreet) -- Boston Therapeutics new PAZ320 tablet is designed to reduce a person's sugar intake before eating a meal.

VIDEO TRANSCRIPT:

Debra Borchardt:
Diabetes is a disease that is affecting millions and millions of Americans but there are some companies that are addressing the problems here and taking kind of a novel approach. One of those is Boston Therapeutics (BTHE) and I'm going to talk to the CEO Dr. David Platt. He has a couple of products and one is PAZ320 and it's a tablet that you take before you eat that reduces the amount of sugar your body absorbs and then another is Ipoxyn and it helps with problems such as foot ulcers. Dr. Platt, let's talk about the first one, the PAZ320. Everything we eat has sugar in it, just everything, so this tablet sounds like it's really gonna help that.

Dr. David Platt:
Absolutely, what we use is called a non-systemic approach. The other drugs, other diabetes drugs, are systemic, goes into the blood and operate only or activate mechanism in the body in the blood. What we do, we have a chemistry that blocks the enzyme in the intestine and as a consequence the sugar in the food is less digested. In our clinical trial we show forty percent reduction of the amount of sugar that goes into the blood. We actually don't reduce the sugar in the blood, we don't let it go up. And the sugar that is not digested by the enzyme goes out to the system.

Debra Borchardt:
Right, and if you've ever tried to eat less sugar you know it is almost impossible. Everything on the shelves has tons and tons of sugar in it. Another issue with diabetic patients, if you have friends or family with diabetes you know that these wounds, these problems that come as a result the disease. This drug Ipoxyn helps the healing in those wounds, right?

Dr. David Platt:
Ipoxyn is basically an anti-necrosis drug and it treats hypoxia or condition of lack of oxygen in the tissue. So [the] wound is usually started by a lack of oxygen. So it's an IV carbohydrate carry oxygenated, injected IV. It goes into the body, picks up an oxygen molecule in releasing next to the wound to treat the hypoxia condition called oxygen therapeutics.

Debra Borchardt:
Alright well these are two very fascinating new products. Now the PAZ320 is being tested now for use with other diabetes drugs but hopefully in the future it will get approved for all of us that want to reduce the amount of sugar in and have tried but but have a hard time doing so, not for diet, just truly for reducing the sugar that is absorbed in your body. That's doctor David Platt, his company is Boston Therapeutics, they're fairly new company traded over-the-counter, and I'm Debra Borchardt with TheStreet.

Written by Debra Borchardt in New York.

Disclosure: TheStreet's editorial policy prohibits staff editors, reporters and analysts from holding positions in any individual stocks.

More from Stocks

Markets Look Confused After Latest Beating

Markets Look Confused After Latest Beating

General Electric Expulsion From Dow Symbolizes Unsettled Week in Markets

General Electric Expulsion From Dow Symbolizes Unsettled Week in Markets

How Small-Cap Stocks Can Protect Your Portfolio From a Trade War

How Small-Cap Stocks Can Protect Your Portfolio From a Trade War

Week Ahead: Trade Fears and Stress Tests Signal More Volatility To Come

Week Ahead: Trade Fears and Stress Tests Signal More Volatility To Come

3 Great Stock Market Sectors Millennials Should Invest In

3 Great Stock Market Sectors Millennials Should Invest In